Cancer treatment has transformed over the last 25 years. Since the first genetically targeted treatments emerged in the 1990s and immune checkpoint inhibitors in the 2010s, oncology has consistently overshadowed other therapy areas. Cancer tops the approved drugs roster, the number and combined value of R&D programs, dealmaking numbers and venture capital investment. Total cancer drug sales of $180bn in 2022 eclipsed other areas and will grow to over $340bn by 2028, according to Evaluate. That’s more than double the next-best placed category, neurology products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
